Dialyzability and Pharmacokinetics of ASP2151 Following Single Oral Dosing in Hemodialysis Patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224180

Enrollment

Registered

2018-12-11

Start date

2019-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis Patients

Interventions

investigational material(s) Generic name etc : ASP2151 INN of investigational material : Amenamevir Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investigational mate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients

Exclusion criteria

Exclusion criteria: - Patients who have significant cardiac, hepatic, pulmonary, blood disease considered inappropriate for participation in clinical trials - Patients with Hepatitis B virus, hepatitis C virus or HIV virus infection - Patients who have an Hb value <9 g/dL at screening - Patients with a history of gastrointestinal surgical operation

Design outcomes

Primary

Measure	Time frame
pharmacokinetics Pharmacokinetics Plasma concentration of ASP2151	—

Secondary

Measure	Time frame
safety Safety assessment Subjective, Objective assessment, Vital sings, Laboratory tests	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026